278 related articles for article (PubMed ID: 31376048)
1. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.
Yogurtcu ON; Sauna ZE; McGill JR; Tegenge MA; Yang H
AAPS J; 2019 Aug; 21(5):96. PubMed ID: 31376048
[TBL] [Abstract][Full Text] [Related]
2. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
[TBL] [Abstract][Full Text] [Related]
3. Applying MAPPs Assays to Assess Drug Immunogenicity.
Karle AC
Front Immunol; 2020; 11():698. PubMed ID: 32373128
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
Karle A; Spindeldreher S; Kolbinger F
MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
Front Immunol; 2020; 11():1301. PubMed ID: 32695107
[TBL] [Abstract][Full Text] [Related]
7. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development.
Lee MV; Saad OM; Wong S; LaMar J; Kamen L; Ordonia B; Melendez R; Hassanzadeh A; Chung S; Kaur S
Front Immunol; 2023; 14():1295285. PubMed ID: 38022649
[TBL] [Abstract][Full Text] [Related]
8. Specificity of the T Cell Response to Protein Biopharmaceuticals.
Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
Front Immunol; 2020; 11():1550. PubMed ID: 32793213
[TBL] [Abstract][Full Text] [Related]
9. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies.
Mattei AE; Gutierrez AH; Seshadri S; Tivin J; Ardito M; Rosenberg AS; Martin WD; De Groot AS
MAbs; 2024; 16(1):2333729. PubMed ID: 38536724
[TBL] [Abstract][Full Text] [Related]
10. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.
Sauna ZE; Lagassé D; Pedras-Vasconcelos J; Golding B; Rosenberg AS
Trends Biotechnol; 2018 Oct; 36(10):1068-1084. PubMed ID: 29908714
[TBL] [Abstract][Full Text] [Related]
11. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of protein therapeutics.
De Groot AS; Scott DW
Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
14. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.
Kropshofer H; Singer T
J Immunotoxicol; 2006 Sep; 3(3):131-6. PubMed ID: 18958693
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics.
Jawa V; Joubert MK; Zhang Q; Deshpande M; Hapuarachchi S; Hall MP; Flynn GC
AAPS J; 2016 Nov; 18(6):1439-1452. PubMed ID: 27450229
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
Krishna M; Nadler SG
Front Immunol; 2016; 7():21. PubMed ID: 26870037
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity assessment during the development of protein therapeutics.
Rosenberg AS; Sauna ZE
J Pharm Pharmacol; 2018 May; 70(5):584-594. PubMed ID: 28872677
[TBL] [Abstract][Full Text] [Related]
18. T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics.
Sun R; Qian MG; Zhang X
MAbs; 2024; 16(1):2324836. PubMed ID: 38512798
[TBL] [Abstract][Full Text] [Related]
19. Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity.
Pratt KP
Antibodies (Basel); 2018 May; 7(2):. PubMed ID: 31544871
[TBL] [Abstract][Full Text] [Related]
20. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.
Sekiguchi N; Kubo C; Takahashi A; Muraoka K; Takeiri A; Ito S; Yano M; Mimoto F; Maeda A; Iwayanagi Y; Wakabayashi T; Takata S; Murao N; Chiba S; Ishigai M
MAbs; 2018; 10(8):1168-1181. PubMed ID: 30199322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
